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Imaginary Worlds: The European Network for Health Technology Assessment (EUnetHTA) 
Recommendations for Health Economic Evaluations 
Paul C. Langley, PhD 
College of Pharmacy University of Minnesota, Minneapolis MN 
 
Abstract 
The European Network for Health Technology Assessment (EUnetHTA) guidelines for health economic evaluations represent a 
consolidated view of non-binding recommendations for assessments of the relative effectiveness of pharmaceuticals or other health 
technologies. EUnetHTA views itself as the scientific and technological backbone of the development of health technology assessment 
in the European Union and among its member states and other partners. Unfortunately, the standards for health technology 
assessment proposed by EUnetHTA do not meet the standards of normal science. They do not support credible claims for the clinical 
and comparative cost-effectiveness of pharmaceuticals. In rejecting the standards of normal science the guidelines put to one side 
the opportunity not only to re-assess and replicate clinical and cost-effectiveness claims but to provide meaningful feedback on 
claims assessment to health care decision makers. The purpose of this review is to make the case that, in failing to support standards 
for experimentation, EUnetHTA is advocating its partners support the creation of modeled or simulated imaginary or false worlds. 
While EUnetHTA is not alone in recommending the construction of imaginary worlds to support formulary decisions, there is still the 
opportunity to revisit these recommendations and decide whether or not to encourage a scientifically rigorous approach to health 
technology assessments - to abandon a commitment to intelligent design in favor of natural selection. 
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Introduction 
A hallmark of health technology assessments is the 
commitment to constructing evidence for the impact of 
products and devices through modeled or simulated 
imaginary worlds where the claims made are impossible to 
evaluate 1 2 3. This is a long standing commitment with 
hundreds of papers published in leading journals all 
subscribing to imaginary world scenarios 4 5 6. At the same 
time, over the past 25 years, a number of countries have 
established guidelines to support technical reviews of 
pharmaceutical products and devices 7 8 9 10. These also 
support the construction of imaginary worlds to make the 
case for formulary placing and pricing 11 12. This is seen most 
clearly in the National Institute for Health and Care Excellence 
(NICE) reference case and its mandating lifetime cost-per- 
quality adjusted life year (QALY) models in chronic disease 13.  
 
At the same time professional and other groups, such as the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) and the Academy of Managed Care 
Pharmacy (AMCP), have also supported the construction of 
imaginary worlds through recommendations for standards in 
modeling clinical and cost-outcomes claims 14 15.  
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Over the past few months, however, there has been an effort 
to point out that, set against the standards of normal science  
in its commitment to hypothesis testing and ongoing 
experimentation, modeled and simulated claims in health 
technology assessments typically fail to meet accepted 
scientific standards. Rather than a commitment to developing 
testable clinical and cost-effectiveness claims, supporting 
replication in target populations and providing feedback to 
health system decision makers, the commitment to non-
testable claims makes any application of the standards and 
processes or normal science impossible. The result, at least in 
the US, is that claims based on models or simulations play 
little, if any role, in health care decision making.  
 
The purpose of this review is to consider whether the 
methods proposed by EUnetHTA for health economic 
evaluations meet the standards of normal science. The 
question raised is whether the standards proposed are 
consistent with, or even recognize, the potential for 
evaluation, falsification and replication in clinical and 
comparative effectiveness claims.  This question applies both 
to the recommendations for health technology assessment as 
well as the associated relative effectiveness 
assessments 16 17 18. 
 
THE EUnetHTA RECOMMENDATIONS 
The purpose of the EUnetHTA guideline is twofold: firstly, to 
set a general framework for how to conduct economic 
evaluations and, secondly, to increase the transferability of 
economic evaluations among EUnetHTA partners. The 
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guideline itself is based on a review of guidelines developed 
by 25 of the 33 countries in the EUnetHTA collaborating 
partnership (28 EU member states together with Norway, 
Switzerland, Russia and Turkey). EUnetHTA was established in 
2006 and is seen as the ‘scientific and technological backbone 
of the health technology assessment development in the 
European Union and its member states’ 19. The present 
recommendations follow from, in European Union 
terminology, the Joint Action 2 (JA2) aim to bring 
collaboration to a higher level in establishing a sustainable 
health technology assessment structure as detailed in the 
May 2016 Final Technical Report 20 . Although the focus here 
is on the recommendations for economic evaluations and 
relative effectiveness assessments (REAs), it should be noted 
that these are elements in the health technology assessment 
CORE model domains which also encompass issues of ethics, 
organizational aspects, patients and social aspects, and legal 
aspects as dimensions of value 21. 
 
Methods for Health Economic Evaluations 
The main recommendations for what EUnetHTA describes as 
the reference case are: 
 
• Type of analysis: results to be presented as both a 
cost-effectiveness (CEA) and cost-utility analysis 
(CUA), with a cost-minimization analysis (CMA) 
where no difference between an intervention and its 
comparator (or a cost-consequences analysis [CCA]) 
• Clinical evidence from a systematic review of the 
literature, with RCTs the most appropriate source 
• Time horizon: long enough to reflect all important 
relevant differences in costs and outcomes between 
the technologies being compared 
• Use of Models: decision model, where choice of 
model depends on research question 
• Perspective: health care and possibly societal 
perspective 
• Costs: resource utilization in units with country 
specific costs 
• Outcome measure: natural units (including life years) 
and as QALYs 
• Discounting: base case discount rate between 3 and 
5 per cent 
• Results: CEA and CUA presented as absolute and 
incremental values 
• Uncertainty: deterministic and probabilistic 
sensitivity analysis 
Although the focus of these reference case recommendations 
is to improve transferability of results between EUnetHTA 
partners through a common report structure, little detail is 
given as to how an economic evaluation is to be undertaken. 
As they stand, they represent a ‘common view’ on which the 
various EUnetHTA partners find basic agreement. The 
recommendations reflect clearly the impact of the NICE 
reference case, although they stop short of the more specific 
requirements for a NICE reference case model including 
recommendations for cost-QALY thresholds.  
 
Relative Effectiveness Assessment 
To clear up any initial confusion: the term relative 
effectiveness assessment does not apply to the formulation 
of comparative clinical and cost-effectiveness claims in a form 
that is amenable to empirical evaluation and replication in 
target populations. Rather, the term applies to: the extent to 
which the effects observed in clinical studies are likely to 
reflect the expected results when a specific intervention is 
applied to the population of interest. The relative 
effectiveness of interventions is to be judged from ‘suitable’ 
clinical trial data; from pragmatic trials that have the ‘noise of 
practice’ rather than from ‘explanatory’ trials conducted 
within a strict trials setting. Given this, the assessor of relative 
effectiveness should always indicate the likeliness that the 
available evidence is applicable to the decision problem.  
 
A completed relative value assessment is intended to provide 
a set of recommendations for the selection and assessment 
of clinical endpoints, broadly categorized as mortality, 
morbidity, clinical status, symptoms, function and health 
related quality of life (HRQoL). In the case of the clinical 
endpoints, the relative effectiveness assessment is regarded 
is a measure of how a patient feels, functions or survives. The 
clinical endpoint should be reproducible and valid, to 
facilitate comparisons across studies and jurisdictions. At the 
same time, in chronic disease they should be long-term or 
final endpoints with all-cause mortality used where relevant 
as it is seen as the most unbiased endpoint. Overall survival is 
the preferred endpoint in survival analyses. Extrapolation 
from intermediate to final endpoints should be underpinned 
by a clear biological or medical rationale or a strong or 
validated link, otherwise the focus should be on intermediate 
endpoints. HRQoL measures are not considered adequate as 
the primary endpoint in a relative value assessment.    
 
Discussion 
The Standards of Normal Science 
The requirement for testable hypotheses to support the 
discovery of new facts is unexceptional. Since the 17th century 
it has been recognized that if a research agenda is to 
advance, if there is to be an accretion of knowledge and if 
models are to generate meaningful hypotheses, then these 
hypotheses must be such that they can be empirically 
evaluated. This position has been well documented by 
Wootton in his reassessment of the use of language in the 
idea of the scientific revolution in The Invention of Science22 . 
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If a model fails to generate testable or measurable 
hypotheses, then it should be seen as simply a construct to 
support the exploration of imaginary worlds or thought 
experiments and not part of a meaningful research program; 
a program that underpins the notion of progress in the 
accumulation of knowledge. Consider the motto of the Royal 
Society, first meeting in 1660 and a Royal Charter in 1662, 
nullius in verba – ‘take no man’s word for it’.  
 
Replication and Claims Assessment 
By the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper in his 
advocacy of a process of ‘conjecture and refutation’23 24 .  
Hypotheses or claims must be capable of falsification; indeed 
they should be framed in such a way that makes falsification 
likely. Life becomes more interesting if claims are falsified 
because this forces us to reconsider our models and the 
assumptions built into those models. At the same time there 
is the need for replication. This has been brought home in the 
last few years by attempts to replicate clinical trial and 
laboratory claims. There has been increasing concern 
expressed over the presence of repetitive flaws and the need 
for guidelines to improve experimental reproducibility. As 
noted in a recent editorial in Nature applicants to the 
National Institutes of Health (NIH) are now required ‘to 
explain the scientific premise behind their proposals and 
defend the quality of their experimental design’ 25.  
 
More recently, Camerer et al in their evaluation of laboratory 
experiments in economics find, of the 18 studies considered, 
an effect size in the same direction in only 11 replications 
with on average a replicated effect size of 66% of the 
original 26. As the authors note: the deepest trust in scientific 
knowledge comes from the ‘ability to replicate empirical 
findings’ although rarely carried out in the social sciences.  
 
Unfortunately, if these EUnetHTA recommendations reflect a 
common European view on health economic evaluations, 
then they represent a commitment to the creation of 
modeled or simulated imaginary worlds. There is, apparently, 
no concern for the standards of normal science and the 
commitment to evaluable clinical and cost-outcome claims, 
experimentation and replication. There is no concept of a 
research program in economic evaluations to support an 
accumulation and exchange of knowledge between health 
care systems as to the impact of pharmaceuticals and devices 
in target patient populations. 
 
As far as can be ascertained, relative effectiveness 
assessments are not intended to support prospective 
experimentation: the discovery of new facts through 
experimentation and replication of comparative clinical 
claims in target populations. Although those developing a 
relative effectiveness assessment are asked, in the case of 
clinical endpoints, that they be reproducible and valid, this 
refers to the choice of endpoints, in a hierarchy of endpoints. 
The focus is on measures that may support potential 
replication, not on the role of ongoing replication studies to 
assess the merits of clinical claims in target populations.  
 
While this rejection of experimentation may reflect an 
implicit recognition that there are limited data for actually 
evaluating and replicating claims across even a handful of the 
partners under the EUnetHTA umbrella or simply a failure to 
appreciate that the standards of normal science are equally 
applicable in health technology assessments is a moot point. 
The key point is that there is no commitment to hypothesis 
testing. Existing clinical data are taken at face value, 
pragmatic trials may be assigned a greater weight in 
systematic reviews and the assessor’s role is to judge the 
applicability of reported results to the ‘likely’ impact of an 
intervention on target populations in specific jurisdictions. 
Presumably these ‘likely’ claims, assessed treatment benefits, 
are then an input to a decision model to judge, in turn, the 
‘likely’ cost-effectiveness of the intervention in the target 
population in one or more of the EUnetHTA partners’ 
jurisdictions.  There are no recommendations for these 
presumed ‘likelihoods’ to be explored. This is unfortunate 
because the standards proposed for relative effectiveness 
assessments have the potential to provide a robust platform 
both for clinical claims assessment and replication, as well as 
a platform for evaluable cost-outcomes claims. 
 
The EUnetHTA Reference Case Recommendations 
The EUnetHTA recommendations for a base-case reference 
model to support to support the transferability of results 
between consortium partners rests upon a methodology that 
supports the creation of imaginary worlds. Claims for 
comparative cost-outcomes are, given the recommended 
standards, impossible to evaluate. The recommendations 
endorse the creation of lifetime cost-per-QALY claims in order 
to capture, for possibly decades into the future, all relevant 
differences in costs or outcomes, appropriately, discounted, 
between the technologies being compared. Partners to the 
EUnetHTA consortium are encouraged to build their own 
versions of the base case with the result that the various 
partners can then compare their various imaginary world 
constructs and their claims for comparative, constructed cost-
per-QALY estimates.  
 
Unfortunately, apart from the issue of choosing between the 
various generic QALY measures as the outcome ‘gold 
standard’, the principal objection to a cost-per-QALY 
reference case as the basis for transferability of modeled 
claims is that no health system collects QALY measures as a 
standard in, for example, electronic medical records or 
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administrative records. The only way a QALY claim could be 
evaluated (and assuming it was presented in a form that 
could be reported on in a 2-3 year timeframe) would be 
through a comparative prospective observational study. 
Expressing claims in QALY-terms, therefore, sets up an 
immediate barrier to claims evaluation and replication 27.  
 
The commitment in the EUnetHTA recommendation to the 
construction of imaginary worlds puts to one side the 
standards of normal science. Rather than recommendations 
focused on the acceptance of  hypothesis testing, falsification 
and replication in claims made for pharmaceutical products 
and devices, at no stage in the guidelines is there any 
mention of the potential for developing testable claims for 
product impact or the feasibility of evaluating these claims 
through hypothesis testing, falsification and replication. 
These could involve claims, not only for clinical outcomes, but 
adherence and resource utilization in target patient 
populations. To all intents and purpose, if we subscribe to the 
EUnetHTA reference case, the standards of normal science 
appear to have been put to one side in favor of non-evaluable 
claims based on models or simulations 28.  
 
Certainly, attempts to evaluate comparative claims for cost-
effectiveness in many countries are made difficult by the 
absence of data. The EUnetHTA partners are not as well 
served as the United States in access to big data. This is not 
an excuse for asking for formulary decisions to be based on 
constructed simulations that create non-evaluable claims. 
The fundamental objection to simulations driving decision 
making is that there is no opportunity, notably in long term or 
lifetime simulations, to generate feedback. Health systems 
that have relied on reference case modeling and thresholds 
to support formulary decisions have no idea, in the absence 
of experimental data, whether those claims are right or even 
if they are wrong. We also have little guidance as to whether, 
in selecting RCT claims as inputs to models or simulations, 
those claims meet the standards for replication. If not, then 
further uncertainty is cast on the validity of a reference case 
model or simulation. Health system decision makers are, 
therefore, in an unenviable position. If they accept the 
EUnetHTA reference case, then decisions could be challenged 
on the grounds that they lack testable predictions and 
experimental confirmation. If they insist on an appropriate 
evidence base, then they should require manufacturers to 
provide this, putting to one side the reference case 
simulation standards.  
 
Relativism and Comparative Claims 
Acceptance of decisions driven by simulated or modeled 
reference cases is to accept a relativist position. Rather than 
subscribing to the position that the standards of normal 
science are the only standards to apply in health care 
decisions, the relativist believes that all perspectives are 
equally valid. In their advocacy of the equivalence or 
symmetry principle health care decisions are to be 
understood sociologically. No one body of evidence is 
superior to another. Results of a simulation are on an equal 
basis with those of a RCT. Indeed, there is no objection to 
basing clinical claims on simulations in lieu of funding the 
more expensive RCT. For the relativist, and this applies to the 
subject area and community of ‘pharmacoeconomists’, the 
success of a scientific research program, in this case one built 
on models and simulations, rests not on its ability to generate 
new knowledge but on its ability to mobilize the support of 
the EUnetHTA  community. Basing decisions on models and 
simulations underpins the consensus view that evidence is 
constructed, never discovered. Instead of coming to grips 
with reality science is about rhetoric, persuasion and 
authority.  
 
Unfortunately, there are no recognized criteria for choosing 
between modeled or simulated claims that generate 
untestable predictions. They are accepted because their 
proponents believe it is possible to capture the critical or 
similar features of the reality of a decision.  If the simulated 
input conditions and the simulated core mechanism 
correspond to reality, the sufficient condition character of the 
simulation assures us that the output is necessarily entailed 
and predictions must corresponded to reality 29. But 
simulations can be challenged; simulations can fail and 
simulations can be ‘reverse engineered’ to generate required 
comparative effectiveness claims and still meet 
recommended guidelines. Absent the ability to evaluate 
claims, we have no basis for claiming that one simulation, and 
its support for a sponsor’s product is superior to another. The 
claims are immune to failure. 
 
These conclusions hold irrespective of how much we attempt 
to build up the appearance of being scientifically rigorous in 
the validation of models and simulations. We can claim that 
they ‘adequately reflect reality’, we can apply deterministic 
and probabilistic sensitivity analyses, we can produce ICER 
cloud diagrams, we can apply thresholds and we can even 
introduce an analysis of the value of perfect information. 
Nevertheless, the fundamental objection still applies: there 
are no testable predictions and, as such, the simulation fails 
the standards of normal science. They are appropriately 
viewed as pseudoscience; sharing the platform with 
intelligent design and not natural selection 30. 
 
Conclusions 
If we put to one side the EUnetHTA reference case 
recommendations for health technology evaluations, is there 
an acceptable methodology to support health system 
decision making? Recently, the Program in Social and 
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Administrative Pharmacy, University of Minnesota proposed 
guidelines for formulary evaluation that were designed to 
meet the standards of normal science 31. The key points in 
these guidelines are: (i) clinical and cost-outcomes claims 
should evaluable; (ii) claims should be evaluable in a time 
horizon that is meaningful to health care decision makers 
(e.g., feedback in 1-2 years); (iii) if possible, claims should be 
evaluable from existing data sources (e.g., electronic medical 
records); (iv) a protocol detailing how the claims will be 
evaluated should accompany formulary submissions; and (v) 
the protocol-based evaluation should be underwritten by the 
manufacturer.  
 
Whether EUnetHTA is prepared to withdraw their current 
reference case recommendations for health technology 
assessment is an open question. Possibly too much has been 
invested in formulating common-core guidelines to support 
constructed, imaginary world claims to pull back now. Against 
this, there may be individuals within the EUnetHTA 
partnership who may accept the arguments put forward here 
and accept the need to put health care decision making on a 
defensible evidence base.  
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